CLEVELAND CLINIC ABUDHABI L L C

Juvenescence Secures $76M in Series B-1 Funding Led by Abu Dhabi's M42 for Age-Related Disease Therapeutics

4 days ago

• Juvenescence has raised $76 million in the first tranche of its Series B-1 financing round, led by Abu Dhabi's M42, to advance its clinical pipeline targeting age-related diseases. • The funding is part of a strategic partnership with M42 to establish a drug development hub in Abu Dhabi, combining M42's healthcare data expertise with Juvenescence's AI-enabled discovery technology. • Juvenescence aims to complete the full financing in Q3 2025, supporting its transition to a clinical-stage biotech company developing novel medicines that target core aging mechanisms.

Cleveland Clinic Abu Dhabi Pioneers First GCC Breast Cancer Recurrence Trial with AstraZeneca

4 months ago

• The Fatima bint Mubarak Center at Cleveland Clinic Abu Dhabi becomes the first GCC facility to join a global Phase 3 trial testing a novel SERD anti-estrogen medication for breast cancer recurrence prevention. • The groundbreaking study, funded by AstraZeneca, involves 5,500 participants worldwide and aims to establish a new standard of care by comparing the novel drug against existing hormone therapies. • In the UAE, where breast cancer accounts for 11.6% of annual cancer deaths, this trial represents a significant step toward addressing regional health inequities and advancing cancer treatment options.

Medicus Pharma Advances Non-Invasive Basal Cell Carcinoma Treatment with Phase 2 Trial and Asia-Pacific Expansion

6 months ago

• Medicus Pharma's Phase 2 trial of SKNJCT-003, a non-invasive treatment for basal cell carcinoma (BCC), has randomized over 50% of the targeted 60 patients in the US. • The company plans to submit interim data to the FDA in Q2 2025, seeking a Type C meeting to fast-track the clinical development program. • Medicus Pharma is collaborating with Swanielle to explore expanding the Phase 2 clinical study into the Asia-Pacific region, targeting areas with limited surgical options. • A previous Phase 1 study showed promising results, with six of thirteen patients experiencing complete clinical responses to D-MNA treatment.